New hope for Tough-to-Treat T-Cell lymphoma: experimental therapy MB-105 enters phase 2
NCT ID NCT06534060
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 22 times
Summary
This study tests an experimental drug called MB-105 in about 46 adults with a specific type of T-cell lymphoma (CD5-positive) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink or control the cancer and to check for side effects. Participants will receive MB-105 and be monitored for tumor response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Cleveland Clinic
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Moffitt Cancer Center Magnolia Campus
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregan Health & Science University
NOT_YET_RECRUITINGPortland, Oregon, 97239, United States
Contact
-
SCRI - Colorado Blood Cancer Institute (CBCI)
NOT_YET_RECRUITINGDenver, Colorado, 92037, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Nebraska
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of San Diego (UCSD)-Moores Cancer Center
RECRUITINGSan Diego, California, 92037, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.